ATE283860T1 - Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren - Google Patents

Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren

Info

Publication number
ATE283860T1
ATE283860T1 AT00941321T AT00941321T ATE283860T1 AT E283860 T1 ATE283860 T1 AT E283860T1 AT 00941321 T AT00941321 T AT 00941321T AT 00941321 T AT00941321 T AT 00941321T AT E283860 T1 ATE283860 T1 AT E283860T1
Authority
AT
Austria
Prior art keywords
ability
hormone receptors
organosilicon compounds
cell nuclear
receptors localized
Prior art date
Application number
AT00941321T
Other languages
English (en)
Inventor
Richard L Beard
Michael Garst
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE283860T1 publication Critical patent/ATE283860T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/0805Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
    • C07F7/0807Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms comprising Si as a ring atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00941321T 1999-06-11 2000-06-09 Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren ATE283860T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13873199P 1999-06-11 1999-06-11
PCT/US2000/015972 WO2000077011A1 (en) 1999-06-11 2000-06-09 Organosilyl compounds having nuclear hormone receptor modulating activity

Publications (1)

Publication Number Publication Date
ATE283860T1 true ATE283860T1 (de) 2004-12-15

Family

ID=22483369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941321T ATE283860T1 (de) 1999-06-11 2000-06-09 Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren

Country Status (11)

Country Link
US (1) US6452032B1 (de)
EP (1) EP1185539B1 (de)
JP (1) JP2003502337A (de)
CN (1) CN1368975A (de)
AT (1) ATE283860T1 (de)
AU (1) AU774538B2 (de)
BR (1) BR0011741A (de)
CA (1) CA2375797A1 (de)
DE (1) DE60016404T2 (de)
HK (1) HK1047752A1 (de)
WO (1) WO2000077011A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144360A1 (en) * 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
HUP0500096A3 (en) * 2001-12-19 2012-08-28 Bristol Myers Squibb Co Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function, process for producing them and pharmaceutical compositions containing them
EP1465882B1 (de) * 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
AU2003286245A1 (en) * 2002-11-25 2004-06-18 Amedis Pharmaceuticals Ltd. Silicon compounds to be used as ligands for retinoid receptors
US7618956B2 (en) * 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
EP2545964A1 (de) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen
US10940127B2 (en) 2015-11-25 2021-03-09 Io Therapeutics, Inc. Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
JP2019517557A (ja) 2016-06-10 2019-06-24 アイオー セラピューティクス インコーポレイテッド 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
EP4424364B1 (de) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Kombinationen zur verwendung bei der behandlung von zirrhose und leberfibrose
AU2018301810A1 (en) 2017-07-13 2020-01-23 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
US10363272B2 (en) 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
CN115246856A (zh) * 2021-04-27 2022-10-28 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5053523A (en) 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
IE920949A1 (en) 1991-03-26 1992-10-07 Allergan Inc Chromans and thiochromans with heteroarylethynyl¹substituents at the 7-position having retinoid-like¹biological activity
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
JP2856175B2 (ja) * 1996-10-25 1999-02-10 日本電気株式会社 液晶添加剤、液晶組成物およびそれを用いた液晶表示素子
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism

Also Published As

Publication number Publication date
CN1368975A (zh) 2002-09-11
CA2375797A1 (en) 2000-12-21
HK1047752A1 (zh) 2003-03-07
DE60016404D1 (de) 2005-01-05
AU774538B2 (en) 2004-07-01
US6452032B1 (en) 2002-09-17
BR0011741A (pt) 2002-03-19
WO2000077011A1 (en) 2000-12-21
EP1185539B1 (de) 2004-12-01
AU5604000A (en) 2001-01-02
JP2003502337A (ja) 2003-01-21
DE60016404T2 (de) 2005-10-27
EP1185539A1 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
ATE283860T1 (de) Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren
Stolen et al. Optical Kerr effect in glass waveguide
DE69911470D1 (de) In situ hergestellter batterieseparator
AU1116400A (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
ATE502320T1 (de) Elektrophoretisches medium versehen mit abstandselementen
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
DE69830970D1 (de) Ausgleich von Nichlinearitäten in quadraturmodulationbenutzenden Sendern
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
GB9706654D0 (en) Disassociation of interacting molecules
DE60139975D1 (de) Gleichstrom-Leistungsversorgung mit Anwendung von Brennstoffzellen
BR0016520A (pt) Processo para a redução eletroquìmica de corantes reduzìveis
ES2172899T3 (es) Soporte de aplicacion basada en dos para un modem sin controlador.
ATE521599T1 (de) Heterocyclische modulatoren von nukleären rezeptoren
EP0631340A3 (de) Elektrochemisches Element mit flüssigem organischem Elektrolyten.
MX9704501A (es) Moduladores de la funcion de receptores de fas/ap01.
DE69215133D1 (de) Lithium Akkumulator mir flüssigem organischem Elektrolyt
DE69023013D1 (de) Elektrooptischer Modulator mit gekoppelter Quantum-Well-Struktur.
IL200132A0 (en) Method for cell adhesion and wound healing
DE60141483D1 (de) Breitband-elektrooptische modulatoren
DE69634774D1 (de) Modulatoren von regulationsproteinen
PT995146E (pt) Dispositivo electrocromico
EA200000961A1 (ru) Модуляторы функций рецепторов семейства рецепторов tnf/ngf и других белков
ATE328580T1 (de) Antitranspirierend wirkende zubereitungen mit einem gehalt an modulatoren von auqaporinen
ATE347159T1 (de) Reduzierung der vorspannung bei räumlichen lichtmodulatoren
ES2145845T3 (es) Procedimiento para el cultivo de hepatocitos bipolares adheridos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties